乙酰半胱氨酸泡腾片合用噻托溴铵吸入剂治疗慢性阻塞性肺疾病的临床分析

目的分析乙酰半胱氨酸泡腾片合用噻托溴铵吸入剂对慢性阻塞性肺疾病(COPD)患者的临床疗效。 方法选择2018年4月至2020年10月我院收治的COPD患者124例，分为观察组63例，对照组61例。给予对照组噻托溴铵吸入剂及其它常规治疗，观察组在对照组的治疗基础上加用乙酰半胱氨酸泡腾片治疗。比较两组治疗前及治疗3个月时的肺功能指标值、血气指标值及血清炎性因子水平；比较两组治疗3个月时的气流受限严重程度及呼吸困难程度。 结果治疗3个月时，两组患者的FEV₁、FVC、FEV₁/FVC值较治疗前提高，观察组高于对照组(P<0.05)，两组血清IL-6、INF-γ、TNF-α水平较治疗前降低；观察组治疗3个月时的PaO₂值高于对照组，PaCO₂低于对照组，组间比较差异有统计学意义(P<0.05)；治疗3个月时的气流受限程度两组间比较差异有统计学意义(P<0.05)。 结论乙酰半胱氨酸泡腾片联合噻托溴铵吸入剂治疗COPD具有较好临床疗效。

Clinical analysis of acetylcysteine effervescent tablets combined with tiotropium bromide inhalation in the treatment of patients with chronic obstructive pulmonary disease

ObjectiveTo explore the application effects of acetylcysteine effervescent tablets combined with tiotropium bromide inhalation on patients with COPD (chronic obstructive pulmonary disease), so as to provide a method for the disease. Methods124 patients with COPD who were treated in the hospital were selected between April 2018 and October 2020 and were divided into 63 cases in observation group and 61 cases in control group. Control group was given tiotropium bromide inhalation and other conventional treatments, and observation group was combined with acetylcysteine effervescent tablets based on control group. The lung function indexes, blood gas indicators and levels of serum inflammatory factors were compared between the two groups before treatment and at 3 months of treatment. The airway limitation severity and dyspnea degree were compared between the two groups at 3 months of treatment. ResultsAt 3 months of treatment, the FEV₁, FVC and FEV₁/FVC of the two groups were significantly enhanced compared with those before treatment, and the above indexes of observation group were significantly higher than those of control group (all P<0.05). The levels of serum IL-6, INF-γ and TNF-α were significantly reduced in the two groups compared to before treatment, and the levels of observation group were significantly lower than those of control group (all P<0.05). The PaO₂ of observation group at 3 months of treatment was significantly higher compared with that of control group while the PaCO₂ was significantly lower compared to control group (all P<0.05). The airflow limitation severity at 3 months of treatment was significantly milder in observation group than that in control group, and the dyspnea grading was significantly lower than that in control group (all P<0.05). ConclusionAcetylcysteine effervescent tablets combined with tiotropium bromide inhalation has a good application effect on patients with COPD.